Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study

Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study

Abstract Background Ruxolitinib improves splenomegaly and symptoms in patients with intermediate-2 or high-risk myelofibrosis; however, nearly half develop grade 3/4 anemia and/or thrombocytopenia, necessitating dose reductions and/or transfusions. We report findings from an open-label phase 2 study...

Full description

Bibliographic Details
Main Authors: Moshe Talpaz, Susan Erickson-Viitanen, Kevin Hou, Solomon Hamburg, Maria R. Baer
Format: Article
Language:English
Published: BMC 2018-08-01
Series:Journal of Hematology & Oncology
Subjects:
Anemia
Janus kinase
Myelofibrosis
Ruxolitinib
Thrombocytopenia
Transfusion
Online Access:http://link.springer.com/article/10.1186/s13045-018-0642-0

Internet

http://link.springer.com/article/10.1186/s13045-018-0642-0

Similar Items